Driving Breakthroughs in Healthcare, One Bold Idea at a Time

Featured

13 October 2026

Genesys Capital Announces Second Close of Genesys University Seed Fund, Welcoming Sunnybrook and UHN as Hospital Partners

Two of Canada's leading research hospitals join the fund, strengthening pathways from discovery to patient impact and supporting Ontario’s life science ecosystem

Latest

Specific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS

02 November 2026

Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial

24 July 2026

Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026

15 July 2026

All Articles

04 November 2024

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

31 October 2024

Feldan Therapeutics announces the treatment of the first patient in the phase 1/2a clinical trial of its candidate fld-103, against Basal Cell Carcinoma

30 October 2024

Kapoose Creek Bio Acquires Exclusive License to Adapsyn Bioscience’s World-Leading AI Technology for Drug Development

20 September 2024

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

04 September 2024

Feldan Therapeutics Completes a US$ 21 Million Series B financing co-led by Genesys Capital and Fonds de Solidarité Ftq

24 June 2024

Driving Breakthroughs in Healthcare, One Bold Idea at a Time

Featured

Genesys Capital Announces Second Close of Genesys University Seed Fund, Welcoming Sunnybrook and UHN as Hospital Partners

Latest

Specific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS

Robotic Radical Prostatectomy Comes Up ‘Short’ in CAPTAIN Trial

Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026

All Articles

Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025

Feldan Therapeutics announces the treatment of the first patient in the phase 1/2a clinical trial of its candidate fld-103, against Basal Cell Carcinoma

Kapoose Creek Bio Acquires Exclusive License to Adapsyn Bioscience’s World-Leading AI Technology for Drug Development

Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed

Feldan Therapeutics Completes a US$ 21 Million Series B financing co-led by Genesys Capital and Fonds de Solidarité Ftq

Two Genesys co-creations listed on Fierce's Top 10 smartest deals in biopharma